Autologous CAR T cell therapies

Rubrik: Technik

(Treffer aus pharmind, Nr. 10, Seite 938 (2025))

Müller-Tiemann B | de Lageneste M

Autologous CAR T cell therapies / The path ahead · Müller-Tiemann B, de Lageneste M · Cytiva
CAR T cells Cell Therapy Automation Modular manufacturing Bioprocessing Chimeric antigen receptor (CAR) T cell-based therapies have been playing an increasingly large role in the treatment of patients with hematological malignancies. Currently, the US Food and Drug Administration (FDA) has approved CAR T cell therapies for relapsed and/or refractory B-cell lymphoma, mantle cell lymphoma, B acute lymphoblastic leukemia, and multiple myeloma, with a continuously increasing number of clinical trials being reported annually [ 1 ]. Despite the remarkable clinical success – with approximately 25,000 patients treated across 10 commercially available CAR T products – significant manufacturing challenges persist that limit broader accessibility and affordability ...